Skip to main content

Table 2 Results for molecular markers analysed

From: Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab

  Whole group (n = 46)
BRAFV600E  
Mut 2 (4%)
Wild Type 44 (96%)
PIK3CA exon 20  
Mut 3 (6%)
Wild Type 43 (94%)
EGFR FISH GCN  
<2.6 18 (39%)
≥2.6 28 (61%)
HER 3 IHC Score  
>8 20 (44%)
≤8 26 (56%)
IGF-1 IHC Score  
≥2 16 (35%)
<2 30 (65%)